Overview

The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
We, the researchers at the Indiana University School of Medicine, are doing this study to better understand how the effects of certain medications are altered when taken simultaneously, or in combination with each other. We will also look at how each volunteer's genes (DNA) may affect the way these medications are metabolized. Hypothesis: We will test the hypothesis that the extent of drug-drug interaction caused by the combination of erythromycin and diltiazem is not predictable from the extent of interaction produced by each inhibitor alone. Specifically we will test the hypothesis that the combination of erythromycin and diltiazem will cause a greater decrease in midazolam intravenous and oral clearance than the sum of the decreases caused by each inhibitor alone.
Phase:
Phase 4
Details
Lead Sponsor:
Indiana University School of Medicine
Treatments:
Diltiazem
Erythromycin
Erythromycin Estolate
Erythromycin Ethylsuccinate
Erythromycin stearate